Clinical relevance of BKM120 was further confirmed on primary AML samples obtained from de novo and chemo-resistant patients with different PI3K/Akt/mTOR pathway activation and on MNCs obtained from healthy volunteers. Here, MTOR is linked to acute myeloid leukemia.